This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Zi Jun Emma Wang, PhD
Chief Technology Officer at YolTech Therapeutics


Dr. Emma Wang is the chief technology offer and co-founder at YolTech Therapeutics. Her focus is on advancing the non-viral delivery platform to support in vivo gene therapy development through research in novel lipid discovery, product development, process development, characterization as well as GMP manufacture. Prior to joining YolTech, Emma held research positions of growing responsibilities at Providence Therapeutics and Beam Therapeutics. Emma holds a Ph.D. in Chemistry as a member of Prof. Katharina Landfester's group from Max Planck Institute for Polymer Research in Germany, a M.Eng and B.Eng in Chemical Engineering from McGill University in Canada.

Agenda Sessions

  • In vivo Genome Editing: Translating Science from Bench to Bedside